Outro Raises $7M Seed to Scale Integrated Deprescribing Network

Outro Secures $7M Seed Round

Outro, a New York-based digital health company, has raised $7 million in Seed funding. The round was announced on October 8, 2026, and included participation from Actions Capital, Hannah Grey Ventures, SemperVirens, Listen Ventures, LAUNCH, Pave Health Ventures, Cake Ventures, and Brock Recovery Group. No lead investor was disclosed.

What Outro Does

Outro is building an integrated deprescribing network that helps patients safely discontinue psychiatric medications, starting with antidepressants. Its Taper Management program pairs specially trained clinicians with evidence-informed hyperbolic tapering protocols, patient monitoring, and psychosocial support. The program is currently available in 14 US states.

The company was co-founded by CEO Brandon Goode and Dr. Mark Horowitz, author of the Maudsley Deprescribing Guidelines. This clinical leadership underpins Outro's approach to safe medication discontinuation, a growing area of need as more patients seek to come off long-term psychiatric treatments.

The Market Opportunity

Deprescribing represents a significant and underserved segment of digital health. While much attention has focused on mental health treatment initiation, far less infrastructure exists for patients who need structured, safe support to stop medications. Outro's integrated model combines clinical expertise, evidence-based protocols, and continuous patient monitoring—elements that are often missing from general telehealth offerings.

By focusing first on antidepressants, Outro addresses a large patient population. The company's expansion to 14 states indicates early traction and a scalable care model. The involvement of Brock Recovery Group among the investors suggests strategic interest from organizations familiar with behavioral health and recovery services.

Use of Funds

While the company did not specify exact allocations, Seed funding at this stage typically supports clinical network expansion, technology development, and geographic growth. For Outro, priorities are likely to include adding more trained clinicians, extending state coverage beyond the current 14, and enhancing its monitoring and support platform.

Acquisition Relevance

For acquirers in digital health, behavioral health, or telehealth, Outro represents a differentiated asset. Its specialized focus on deprescribing—rather than general mental health—creates a defensible niche with clinical credibility. The co-founding team includes a recognized authority in the field, which adds both scientific validation and potential for guideline-aligned care pathways.

The investor syndicate includes funds with healthcare and consumer expertise, suggesting confidence in both clinical outcomes and scalable delivery. As payers and providers increasingly seek solutions for medication optimization and polypharmacy, Outro's integrated network could become an attractive acquisition target for companies looking to broaden their behavioral health offerings or add deprescribing capabilities.

Key Facts

• Company: Outro
• Headquarters: New York
• Focus: Integrated deprescribing network for psychiatric medications, starting with antidepressants
• Program: Taper Management, available in 14 US states
• Co-founders: CEO Brandon Goode and Dr. Mark Horowitz
• Round: Seed
• Amount: $7,000,000 USD
• Date: October 8, 2026
• Investors: Actions Capital, Hannah Grey Ventures, SemperVirens, Listen Ventures, LAUNCH, Pave Health Ventures, Cake Ventures, Brock Recovery Group
• Lead Investor: Not disclosed

Outro's Seed round positions it to expand a clinically grounded approach to a problem that affects millions of patients. As the company grows its state footprint and clinical network, it will be one to watch in the evolving digital health landscape.